NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Phase 1

Recruiting

Conditions: Kaposi Sarcoma

Interventions: Drug: NHS-IL12
Drug: M7824

First Posted Date: 2020-03-10

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT04303117

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1

Recruiting

Conditions: Adult T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma
HTLV-1 Infection
Chronic Adult T-Cell Leukemia/Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2020-03-09

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT04301076

Locations: 🇺🇸
NYU Langone Hospital - Long Island, Mineola, New York, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 16 locations

Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

Phase 2

Completed

Conditions: Anxiety

Interventions: Device: Pico G2 4K Headset with Applied VR software

First Posted Date: 2020-03-09

Last Posted Date: 2025-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT04301089

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1

Terminated

Conditions: Breast Cancer
Triple Negative Breast Cancer
HER2+ Breast Cancer
Hormone Receptor Negative Breast Cancer
Metastatic Breast Cancer

Interventions: Biological: Brachyury-TRICOM
Biological: M7824
Drug: Entinostat
Biological: Ado-trastuzumab emtansine

First Posted Date: 2020-03-05

Last Posted Date: 2022-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT04296942

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Phase 2

Active, not recruiting

Conditions: Chronic GVHD

Interventions: Drug: Ibrutinib
Diagnostic Test: ECG
Diagnostic Test: PFT's
Diagnostic Test: CT
Drug: Steroid pulse (prednisone)
Drug: Voriconazole
Drug: Posaconazole
Drug: Azithromycin
Drug: Montelukast
Drug: Budesonide
Drug: Beclomethasone
Other: Filgrastim
Other: Pegfilgrastim
Other: Erythropoietin
Other: Transfusions
Procedure: Oral/Skin biopsy

First Posted Date: 2020-03-04

Last Posted Date: 2025-01-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT04294641

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Washington University, School of Medicine, Saint Louis, Missouri, United States

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Refractory Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
HER2-Positive Breast Carcinoma
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Trastuzumab Deruxtecan

First Posted Date: 2020-03-04

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT04294628

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States

and more 3 locations

STOP-T1D Low-Dose (ATG)

Phase 2

Active, not recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Antithymocyte Globulin
Drug: Placebo (for ATG)

First Posted Date: 2020-03-02

Last Posted Date: 2024-10-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 101

Registration Number: NCT04291703

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇦🇺
Queensland Children's Hospital, South Brisbane, Queensland, Australia
🇺🇸
University of California - San Francisco, San Francisco, California, United States

and more 19 locations

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Phase 1

Active, not recruiting

Conditions: Cervical Cancer
Oropharyngeal Cancer
Anal Cancer
HPV Cancers
Vulvar, Vaginal, Penile, Rectal Cancer

Interventions: Biological: PDS0101
Biological: M7824
Biological: NHS-IL12

First Posted Date: 2020-02-27

Last Posted Date: 2025-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT04287868

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy

Interventions: Drug: Azacitidine
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Venetoclax
Biological: Pembrolizumab

First Posted Date: 2020-02-26

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT04284787

Locations: 🇺🇸
Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut, United States
🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 26 locations

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Phase 2

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Recurrent Ependymoma
Recurrent Hepatoblastoma
Recurrent Langerhans Cell Histiocytosis
Recurrent Rhabdoid Tumor
Recurrent Rhabdoid Tumor of the Kidney
Recurrent Adrenal Gland Pheochromocytoma
Recurrent Malignant Glioma
Recurrent Non-Hodgkin Lymphoma
Recurrent Osteosarcoma

Interventions: Drug: Tipifarnib

First Posted Date: 2020-02-26

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT04284774

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 169 locations

Home Terms & Conditions Privacy Policy